Quidel to Present at Upcoming Conferences
November 14 2019 - 6:00PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it will present
at the following upcoming conferences:
- 31st Annual Piper Jaffray Healthcare Conference to be held at
the Lotte New York Palace hotel in New York, New York on Wednesday,
December 4, 2019 at 2:00 p.m. Eastern Time (11:00 a.m. Pacific
Time).
- Evercore ISI 2nd Annual HealthCONx Conference, to be held at
the Four Seasons Boston hotel in Boston, Massachusetts on Thursday,
December 5, 2019 at 1:15 p.m. Eastern Time (10:15 a.m. Pacific
Time).
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present on the specified
days with question-and-answer sessions scheduled immediately
following each presentation. During the presentations, the company
will discuss business and financial developments and trends. The
company's statements may contain or constitute material information
that has not been previously disclosed.
A live webcast and audio archive of each presentation will be
available via the Investor Relations section of the company’s
website at http://ir.quidel.com or by clicking the links below.
Piper Jaffray:
https://event.webcasts.com/starthere.jsp?ei=1271732&tp_key=0c156c3f36
Evercore ISI: http://wsw.com/webcast/evercore4/qdel
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s website for 30 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and
fecal occult blood. Quidel's recently acquired Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide diagnostic answers for quantitative BNP, CK-MB, d-dimer,
myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s
research and development engine is also developing a continuum of
diagnostic solutions from advanced immunoassay to molecular
diagnostic tests to further improve the quality of healthcare in
physicians’ offices and hospital and reference laboratories. For
more information about Quidel’s comprehensive product portfolio,
visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191114005606/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024